Augustine Therapeutics has successfully secured €78 million in Series A funding to further its development of novel therapies. The company is focused on inhibiting the HDAC6 enzyme to treat neuromuscular, neurodegenerative, and cardio-metabolic diseases. Their approach utilizes a unique, non-hydroxamate and non-hydrazide producing chemotype, which aims to be more selective and safer than previous HDAC6 inhibitors. The lead program, AGT-100216, is intended for the treatment of Charcot-Marie-Tooth Disease and will advance into clinical trials with this funding. The financing was led by Novo Holdings and Jeito Capital, with participation from existing and new investors.Podcast creator page: http://santarovich.tilda.ws/Support our podcast with your donations: https://paypal.me/OlgaSantarovich

Ver todos los episodios